Website is intended for physicians
Search:

 

Abstract:

Aim: was to analyze the first experiment and estimate the tolerability of intra-arterial use of the Abraxane in oil chemoembolization in patients with pancreatic adenocarcinoma.

Material and methods: for the period January 2018 - August 2018 г on the basis of the FSCU RIS RHT named after academician A.M. Granov, 19 patients with histologically verified ductal adenocarcinoma of the pancreas received treatment: intra-arterial oil chemoembolization with the use of the Abraxane.

Results: in 14 (73.6%) patients appeared mild pain syndrome that was not accompanied by marked laboratory changes, against the background of standard conservative prophylaxy. In 5 (26.4%) cases, patients had clinical and laboratory signs of postembolization syndrome, which was regarded as adverse events of grade 3 antitumor therapy, manifested by clinical and laboratory signs of mild acute pancreatitis, treated in all cases conservatively

The treatment of the postembolization syndrome lasted up to 7 days, until complete laboratory markers normalization, consisting in reducing the activity of blood amylase and urinary diastase to normal values. In all cases, postembolization syndrome was stopped conservatively In described 5 (26.4%) patients, adverse events of intra-arterial oil chemoembolization were regarded as mild postembolization pancreatitis. After treatment, a decrease in the tumor marker CA 19-9 was observed in 9 (90%) patients.

At the next stage, all patients with localized forms of the tumor underwent surgical treatment in the volume of pylorus-preserving pancreatoduodenal resection (n = 13) from 7 to 15 days after intra- arterial oil chemoembolization.

Conclusion: the procedure of oil chemoembolization with Abraxane can be considered as safe if dosages of the oil radiopaque drug Lipiodol are adeqate. There was a tendency to a decrease in the level of the tumor marker CA 19-9 in the blood of patients after the procedure. 

 

References

1.      Davydov MI, Aksel' EM. Statistics of malignant tumors in Russia and the CIS countries in 2012. Izdatel'skaya gruppa RONTs. 2014; 4: 226 [In Russ].

2.      Siegel R.L., Jemal А. Cancer statistics. CA. Cancer J Clin. 2018; 68: 7-30.

3.      Kaprin AD, Starinsky VV, Petrova GV. Statistics of malignant tumors in Russia 2016 (morbidity and mortality) M.: MNIOI im. PA. Gertsena filial FGBU «NMITs radiologii» Minzdrava Rossii. 2018; 250 p [In Russ].

4.      Alexakis N. Current standards of surgery for pancreatic cancer. Br J Surg. 2004; (11) 91: 1410-27.

5.      Dennison AR. Laparoscopic pancreatic surgery: a review of present results and future prospects. HPB (Oxford). 2010; 4(12): 239-43.

6.      Yang ZYYuan JQ, Di MY Zheng DY Chen JZ, Ding H, Wu XY, Huang YF, Mao C, Tang J.L. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8(3):e57528. doi: 10.1371/journal.pone.0057528. Epub 2013 Mar 5.

7.      Hidalgo M. Pancreatic cancer. N Engl j med. 2010; 362: 1605-17.

8.      Burris H.A. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J ClinOncol. 1997; 2403-13.

9.      Popova AS, Pokataev I A, Tyulyandin S.A. Combined chemotherapy regimens for pancreatic cancer. Zhurnal Meditsinskii sovet, Izdatel'stvo «GRUPPA REMEDIUM». 6: 62-70 [In Russ].

10.    Pokataev I A, Bazin I S, Popova A S, Podluzhnyi D V. Efficacy and safety of induction chemotherapy according to the FOLFIRINOX scheme with borderline resectable and unresectable pancreatic cancer. Nauchno-prakticheskii zhurnal po onkologii «Zlokachestvennye opukholi». 2018; 8(1): 38-47[ In Russ].

11.    Conroy T, Desseigne F, Ychou M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 19(364): 1817-25.

12.    Stocken DD. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005; 8(92): 1372-81.

13.    Desai N, Trieu V, Yao Z. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 1(4): 1317-24.

14.    Dranitsaris G, Yu B, Wang L. Abraxane versus Taxol for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective. J Oncol Pharm Pract. 2016; 2: 205-11

15.    Giordano G, Pancione M, Olivieri N. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol. 2017; 23(32): 5875-5886.

16.    Ottaiano A. Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples. Anticancer Res. 2017; 4(37): 1975-1978.

17.    Von Hoff DD. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. ClinOncol. 2011; 29(34): 454854.

18.    Granov DA, Polikarpov AA, Pavlovskij AV, Moiseenko VE, Popov SA. Evaluation of the safety of intra-arterial chemotherapy with gemcitabine and oxaliplatin in the combined treatment of pancreatic head adenocarcinoma. Annaly khirurgicheskoy gepatologii. 2017; 22 (2): 54-59 [InRuss].

19.    Granov DA., Pavlovskij AV, Suvorova JuV, Gulo AS, Popov SA, Shapoval SV, Tlostanova MS. Neoadjuvant intra-arterial oil chemoembolization and adjuvant regional chemoinfusion in combined treatment of pancreatic cancer. Voprosioncologii. 2008; 54(4): 501-503.

ANGIOLOGIA.ru (АНГИОЛОГИЯ.ру) - портал о диагностике и лечении заболеваний сосудистой системы